DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Bravelle (Urofollitropin) - Maternal Exposure During Pregnancy - Suspected Cause - Side Effect Reports

 
 



Index of reports > Cases with Maternal Exposure During Pregnancy (1)

Below is the selection of side effect reports (a.k.a. adverse event reports) related to Bravelle (Urofollitropin) where reactions include maternal exposure during pregnancy. The selected reports were submitted to the FDA during the sample period of about a year.

Possible Bravelle side effects in female

Reported by a consumer/non-health professional from United States on 2011-10-19

Patient: female, weighing 79.4 kg (174.6 pounds)

Reactions: Maternal Exposure During Pregnancy, Abortion Spontaneous

Drug(s) suspected as cause:
Bravelle
    Dosage: (150 -0225 iu everyday (qd))
    Indication: in Vitro Fertilisation
    Start date: 2009-11-01
    End date: 2009-11-23

Menotropins
    Indication: in Vitro Fertilisation
    Start date: 2009-11-01
    End date: 2009-11-23

Other drugs received by patient: Prenatal Vitamins / 01549301 /; Progesterone

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017